Drugs / CA9hu-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05698238 | Jan 2024 → Jan 2026 overdue | clear cell renal carcinoma, head and neck cancer, malignant mesothelioma, non-small cell lung carcinoma +1 | Mabpro, a.s. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CA9hu-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698238 ↗ |
| Modality | Monoclonal antibody | “Humanized monoclonal antibody to human carbonic anhydrase IX” NCT05698238 ↗ |